The renewal is in the same sentence as the offer
The introductory block gives the intro rate, the amount billed for the first three months, and then states that it renews at a higher monthly rate and what that works out to every three months. Nothing about the second quarter has to be inferred.
Twenty-three of the one hundred and fifty-eight sellers here carry a recorded introductory rate, and the ones that print the standing rate beside it are the minority worth using. Seventy-eight of the one hundred and fifty-eight sellers here carry a headline figure whose real condition is not disclosed; this is not one of them.
Three of the four columns are somebody else
The comparison table sets Coivas against three unnamed providers, with a membership row, a semaglutide row, a tirzepatide row and a clear-pricing row. The seller's own column reads none for membership and marks both drug figures as one flat price after the intro period.
The other three columns carry figures that are noticeably higher, two of them with monthly memberships attached. Those are this seller's account of its rivals and cannot be checked from the page. None of them is recorded on this row.
This matters for anyone reading the page quickly: most of the money on it belongs to companies the page will not name.
Two entities, one brand
The privacy policy names a limited liability company doing business as Coivas. The terms name a differently constituted corporation with the brand name in it, in New York. Both are recorded and neither is chosen.
The table itself is dated, which is rarer than it should be; a priced page that says when its prices were current is a page a reader can age.
No compounding pharmacy is named, no individual clinician is named, and no service area is published.
Coivas's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $149/mothe standing rate after the introductory period, marked "One flat price" in the seller's own comparison table; the other columns of that table are rival sellers and none of their figures is recorded here | September 2026source |
| Tirzepatide (compounded) | $229/mothe standing rate after the introductory period, also marked "One flat price" | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Coivas's current price →Good fit if
- Readers who want the renewal rate and the renewal interval printed beside the introductory rate.
- Buyers who want a seller to state its membership position outright rather than by omission.
- People who value a dated pricing table.
Look elsewhere if
- Anyone who will read a comparison table quickly; most of its figures belong to unnamed rivals.
- Readers who want a single, settled legal entity.
- Buyers who need the pharmacy named.
- People who need a service-area list.
How this review was verified
- Read the weight-loss treatment page, the privacy policy and the terms on 6 September 2026, with a nonsense-path control on the host in the same run.
- Identified which column of the comparison table belongs to this seller before recording any figure, and recorded none of the rival columns.
- Joined adjacent text nodes before matching prices; the intro block splits its figure and its billing amount across elements.
- Recorded both published entity names, from the two documents that carry them.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.